The next chapter of radiopharmaceutical therapy starts now

Leading-edge technologies in the fight against cancer

We are a next generation radiopharmaceutical company, taking cancer head on.

For what’s ahead

Precision is the future of cancer care. Radiopharmaceutical products could offer new hope to patients with cancer.

What to expect

Treatments in development

We are pushing forward the next-generation of radiopharmaceuticals with our exciting pipeline.

About our Pipeline

Focused treatment

With focus and precision, our products direct the power of high energy particles towards cancer - and only cancer.

Learn the science

Clinical trials

Learn more about our ongoing study for Men with Metastatic Castration-Resistant Prostate Cancer. Now enrolling in phase 3.

Splash trial

News + Stories

Press Release
24 Nov

POINT Biopharma Licenses Innovative Lu-177 Production Technology from SCK CEN (Belgian Nuclear Research Center)

POINT Biopharma Global Inc. and Studiecentrum voor Kernenergie/Centre d’Etude de l’Energie Nucléaire, also known as the Belgian Nuclear Research Center (“SCK CEN”) today announced a technology license agreement for Lu-177 purification technology to accelerate POINT’s in-house no-carrier-added lutetium-177 (n.c.a. Lu-177) production program.

Press Release
22 Nov

POINT Biopharma to Host Virtual Education Event on December 6, 2021

POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations. Register online at